Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article

Published:2017-05-23 Issue:7 Volume:41 Page:1381-1382
ISSN:0145-6008
Container-title:Alcoholism: Clinical and Experimental Research
language:en
Short-container-title:Alcohol Clin Exp Res

Author:

Litten Raye Z.¹^ORCID,Falk Daniel E.¹,O'Malley Stephanie S.²,Witkiewitz Katie A.³^ORCID,Mann Karl F.⁴,Anton Raymond F.⁵^ORCID

Affiliation:

1. National Institute on Alcohol Abuse and Alcoholism ; Bethesda Maryland

2. Yale University School of Medicine ; New Haven Connecticut

3. University of New Mexico ; Albuquerque New Mexico

4. Central Institute of Mental Health ; Mannheim Germany

5. Medical University of South Carolina ; Charleston South Carolina

Funder

AbbVie

Alkermes

Ethypharm

Indivior

Eli Lilly and Company

Lundbeck

Otsuka

Pfizer

Arbor Pharmaceuticals

Publisher

Wiley

Subject

Psychiatry and Mental health,Toxicology,Medicine (miscellaneous)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/acer.13411/fullpdf

Reference8 articles.

1. The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders;Anton;Neuropsychopharmacology,2012

2. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials;Falk;Alcohol Clin Exp Res,2010

3. Toward rational, evidence-based, and clinically relevant measures to determine improvement following treatment for alcohol use disorder;Johnson;Alcohol Clin Exp Res,2017

4. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991;Litten;Alcohol Clin Exp Res,1996

5. Development of medications for alcohol use disorders: recent advances and ongoing challenges;Litten;Expert Opin Emerging Drugs,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population;Alcoholism: Clinical and Experimental Research;2018-10-03

2. Overcoming the “Valley of Death” in Medications Development for Alcohol Use Disorder;Alcoholism: Clinical and Experimental Research;2018-07-30

3. FDA and EMA Need Homology on Alcohol Outcome Measures-Semper: Simplicitas est purius modum;Alcoholism: Clinical and Experimental Research;2017-05-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3